Davis Polk and Latham lead on Roche megadeal

A duo of US firms have snared lead roles on Swiss pharmaceutical group Roche's $43.7bn bid for US drug giant Genentech. Davis Polk & Wardwell New York partners Arthur Golden, Chris Mayer and Peter Douglas are advising Roche. It is thought Latham & Watkins' global head of corporate Peter Kerman will lead the firm on advice to existing Latham client Genentech.

Davis Polk and Latham lead on Roche megadeal thelawyer.com thelawyer.com Wed, Jul 23, 2008